Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
7 | 5713 | 34.5 | 82% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1301 | 8126 | ANTIPHOSPHOLIPID SYNDROME//ANTIPHOSPHOLIPID ANTIBODIES//LUPUS ANTICOAGULANT |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | ANTIPHOSPHOLIPID SYNDROME | Author keyword | 1179 | 61% | 22% | 1256 |
2 | ANTIPHOSPHOLIPID ANTIBODIES | Author keyword | 1032 | 65% | 17% | 978 |
3 | LUPUS ANTICOAGULANT | Author keyword | 814 | 71% | 12% | 659 |
4 | ANTICARDIOLIPIN ANTIBODIES | Author keyword | 655 | 69% | 10% | 565 |
5 | BETA2 GLYCOPROTEIN I | Author keyword | 621 | 82% | 6% | 357 |
6 | CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME | Author keyword | 170 | 82% | 2% | 98 |
7 | ANTI BETA2 GLYCOPROTEIN I ANTIBODIES | Author keyword | 168 | 93% | 1% | 64 |
8 | ANTICARDIOLIPIN ANTIBODY | Author keyword | 164 | 64% | 3% | 161 |
9 | ANTICARDIOLIPIN | Author keyword | 127 | 65% | 2% | 122 |
10 | ANTIPHOSPHOLIPID ANTIBODY | Author keyword | 126 | 58% | 3% | 146 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANTICARDIOLIPIN ANTIBODIES | 1741 | 58% | 35% | 1987 |
2 | BETA2 GLYCOPROTEIN I | 1431 | 78% | 17% | 954 |
3 | ANTI BETA2 GLYCOPROTEIN I ANTIBODIES | 463 | 87% | 4% | 227 |
4 | RECOGNIZE BETA2 GLYCOPROTEIN I | 397 | 94% | 2% | 141 |
5 | BETA 2 GLYCOPROTEIN I APOLIPOPROTEIN H | 382 | 94% | 2% | 133 |
6 | INTERNATIONAL CONSENSUS STATEMENT | 316 | 60% | 6% | 343 |
7 | ANTIPHOSPHOLIPID ANTIBODIES | 315 | 32% | 14% | 823 |
8 | ANTI CARDIOLIPIN ANTIBODIES | 303 | 84% | 3% | 166 |
9 | ANTICOAGULANT | 282 | 30% | 14% | 781 |
10 | LUPUS ANTICOAGULANT | 272 | 50% | 7% | 394 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | LUPUS | 69 | 14% | 8% | 473 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | 2006 | 1875 | 123 | 84% |
Medical progress: The antiphospholipid syndrome. | 2002 | 772 | 78 | 92% |
The Pathogenesis of the Antiphospholipid Syndrome | 2013 | 94 | 99 | 71% |
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study | 2015 | 3 | 14 | 93% |
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies | 2015 | 3 | 23 | 87% |
Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment | 2015 | 3 | 144 | 72% |
Diagnosis and management of non-criteria obstetric antiphospholipid syndrome | 2015 | 2 | 58 | 84% |
Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: Analysis of 24 cases from the bibliography review | 2015 | 2 | 23 | 78% |
Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome | 2014 | 16 | 66 | 89% |
Pathogenesis of antiphospholipid syndrome: understanding the antibodies | 2011 | 95 | 77 | 79% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANTIPHOSPHOLIPID STANDARDIZAT | 65 | 95% | 0.4% | 21 |
2 | LUPUS UNIT | 55 | 37% | 2.1% | 120 |
3 | BARBARA VOLCKER WOMEN RHEUMAT DIS | 34 | 69% | 0.5% | 29 |
4 | AUTOIMMUNE DIS | 31 | 19% | 2.6% | 151 |
5 | ALLERGY CLIN IMMUNOL RHEUMATOL UNIT | 19 | 61% | 0.4% | 20 |
6 | CELL CHEM | 15 | 30% | 0.7% | 42 |
7 | SERV MALALTIES AUTOIMMUNES | 14 | 41% | 0.5% | 27 |
8 | CLIN MED DERMATOL | 9 | 30% | 0.5% | 26 |
9 | HLA VASC BIOL | 9 | 52% | 0.2% | 12 |
10 | RIC IMMUNOL CLIN IMMUNOPATOL DOCUMENTAZ M | 9 | 67% | 0.1% | 8 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000124607 | SNEDDONS SYNDROME//SNEDDON SYNDROME//LIVEDOID VASCULOPATHY |
2 | 0.0000119742 | LIBMAN SACKS ENDOCARDITIS//LUPUS MYOCARDITIS//LUPUS CLIN |
3 | 0.0000087015 | MOTHERS RHEUMAT DIS//PREGNANCY RHEUMAT DIS//LUPUS PREGNANCY |
4 | 0.0000079566 | PURTSCHERS RETINOPATHY//PURTSCHER LIKE RETINOPATHY//FROSTED BRANCH ANGIITIS |
5 | 0.0000068481 | THROMBOPHILIA//RECURRENT PREGNANCY LOSS//FACTOR V LEIDEN |
6 | 0.0000056737 | NEUROPSYCHIATRIC LUPUS//NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS//NEUROPSYCHIATRIC SLE |
7 | 0.0000053800 | ANTI ENDOTHELIAL CELL ANTIBODIES//ANTI ENDOTHELIAL CELL ANTIBODY//ANTIENDOTHELIAL CELL ANTIBODIES |
8 | 0.0000053482 | DANISH REGISTER MULTIPLE SCLEROSIS//LUPOID SCLEROSIS//AUTOIMMUNE TAUTOLOGY |
9 | 0.0000036529 | ADRENAL HEMORRHAGE//CYSTIC NEUROBLASTOMA//ADRENAL HEMATOMA |
10 | 0.0000033961 | FACTOR V LEIDEN//APC RESISTANCE//ACTIVATED PROTEIN C RESISTANCE |